Norquetiapine and depressive symptoms in initially antipsychotic-naive first-episode schizophrenia

Journal of Clinical Psychopharmacology

Volumn 33, Issue 2, 2013, Pages 266-269

  Rasmussen, Hans ^a   Ebdrup, Bjørn H ^a   Aggernaes, Bodil ^a   Lublin, Henrik ^a   Oranje, Bob ^a   Pinborg, Lars H ^b,c   Knudsen, Gitte M ^a   Glenthøj, Birte ^a,c  

^a Mental Health Center Glostrup   (Denmark)

^b Rigshospitalet   (Denmark)

^c UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

NORQUETIAPINE; QUETIAPINE; SEROTONIN 2A RECEPTOR; SEROTONIN UPTAKE INHIBITOR; UNCLASSIFIED DRUG;

ANXIETY; BIPOLAR DEPRESSION; DEPRESSION; DSM-IV; HUMAN; ICD-10; LETTER; MAJOR DEPRESSION; MORBIDITY; MORTALITY; POSITIVE AND NEGATIVE SYNDROME SCALE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; SCHIZOPHRENIA; SUICIDE; TREATMENT DURATION;

ADULT; ANTIPSYCHOTIC AGENTS; DEPRESSION; DIBENZOTHIAZEPINES; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; PSYCHIATRIC STATUS RATING SCALES; SCHIZOPHRENIA; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84874930019     PISSN: 02710749     EISSN: 1533712X     Source Type: Journal    
DOI: 10.1097/JCP.0b013e318287acc9     Document Type: Letter

References (18)

1. Siris SG. Depression in schizophrenia: perspective in the era of "atypical" antipsychotic agents. Am J Psychiatry. 2000;157:1379-1389.
2. Addington DD, Azorin JM, Falloon IR, et al. Clinical issues related to depression in schizophrenia: an international survey of psychiatrists. Acta Psychiatr Scand. 2002; 105:189-195. (Pubitemid 34280691)
3. Sands JR, Harrow M. Depression during the longitudinal course of schizophrenia. Schizophr Bull. 1999;25:157-171. (Pubitemid 29104379)
4. Goodwin GM. Evidence-based guidelines for treating bipolar disorder: revised second editionVrecommendations from the British Association for Psychopharmacology. J Psychopharmacol 2009;23:346-388.
5. Jensen NH, Rodriguiz RM, Caron MG, et al. N-desalkylquetiapine, a potent norepinephrine reuptake inhibitor and partial 5-HT1A agonist, as a putative mediator of quetiapine's antidepressant activity. Neuropsychopharmacology. 2008;33:2303-2312.
6. Dell'osso B, Palazzo MC, Oldani L, et al. The noradrenergic action in antidepressant treatments: pharmacological and clinical aspects. CNS Neurosci Ther. 2011;17:723-732.
7. Haenisch B, Bonisch H. Depression and antidepressants: insights from knockout of dopamine, serotonin or noradrenaline re-uptake transporters. Pharmacol Ther. 2011;129:352-368.
8. Rasmussen H, Erritzoe D, Andersen R, et al. Decreased frontal serotonin2A receptor binding in antipsychotic-naive patients with first-episode schizophrenia. Arch Gen Psychiatry. 2010;67:9-16.
9. Rasmussen H, Ebdrup BH, Erritzoe D, et al. Serotonin2A receptor blockade and clinical effect in first-episode schizophrenia patients treated with quetiapine. Psychopharmacology (Berl). 2011;213:583-592.
10. El YM, Battas O, Agoub M, et al. Validity of the depressive dimension extracted from principal component analysis of the PANSS in drug-free patients with schizophrenia. Schizophr Res. 2002;56:121-127. (Pubitemid 34655474)
11. Kramer MS, Vogel WH, DiJohnson C, et al. Antidepressants in 'depressed' schizophrenic inpatients. A controlled trial. Arch Gen Psychiatry. 1989;46:922-928. (Pubitemid 19259540)
12. Kjelby E, Jorgensen HA, Kroken RA, et al. Anti-depressive effectiveness of olanzapine, quetiapine, risperidone and ziprasidone: a pragmatic, randomized trial. BMC Psychiatry. 2011;11:145.
13. Nyberg S, Takano A, Grimm S, et al. PET-measured D2, 5-HT2, and NET occupancy by quetiapine and N-desalkyl-quetiapine in non-human primates. Eur Neuropsychopharmacol 2007;17(suppl 4):254-255.
14. Schou M, Halldin C, Sovago J, et al. PET evaluation of novel radiofluorinated reboxetine analogs as norepinephrine transporter probes in the monkey brain. Synapse. 2004;53:57-67. (Pubitemid 38857641)
15. Siris SG. Diagnosis of secondary depression in schizophrenia: implications for DSM-IV. Schizophr Bull. 1991;17:75-98.
16. Gajwani P, Muzina DJ, Kemp DE, et al. Update on quetiapine in the treatment of bipolar disorder: results from the BOLDER studies. Neuropsychiatr Dis Treat. 2007;3: 847-853.
17. Lipkovich I, Adams DH, Mallinckrodt C, et al. Evaluating dose response from flexible dose clinical trials. BMC Psychiatry. 2008;8:3.
18. Moller HJ, Riedel M, Jager M, et al. Short-term treatment with risperidone or haloperidol in first-episode schizophrenia: 8-week results of a randomized controlled trial within the German Research Network on Schizophrenia. Int J Neuropsychopharmacol. 2008;11:985-997.